FindTrial
Sign In

efficacy of early adalimumab or immunomodulator on postoperative remission maintenance in patients with Crohn's disease

efficacy of early adalimumab or immunomodulator on postoperative remission maintenance in patients with Crohn's disease - postoperative early adalimumab or immunomodulator in CD study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000032485
Enrollment
20
Registered
2018-05-08
Start date
2015-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cron&#39

Interventions

adalimumab azathiopurine

Sponsors

Sakura medical center, Toho university
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: CD patients with intestinal resection for active CD lesion within 3 months

Exclusion criteria

Exclusion criteria: stoma without intestinal resection

Design outcomes

Primary

MeasureTime frame
endoscopic remission rate of 18 months after surgery—

Secondary

MeasureTime frame
clinical remission rate, negative CRP, trough level of anti-TNF agents, maintenance rate of the therapy, re-surgery rate of 18 months after surgery—

Countries

Japan

Contacts

Public ContactAkihiro Yamada

Sakura medical center, Toho university gastroenterology

taro-dog@sakura.med.toho-u.ac.jp043-462-8811

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026